NCT04993677

A Study of SEA-CD40 Given With Other Drugs in Cancers

An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 77 (actual)
• Sponsor: Seagen Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial. In one part, participants have melanoma that has come back after treatment or can't be removed by surgery. Participants in this part will get SEA-CD40 and pembrolizumab. In the other part, participants have non-small cell lung cancer (NSCLC) that has spread through their body. These participants will get SEA-CD40, pembrolizumab, carboplatin, and pemetrexed.

Conditions

• Melanoma
• Carcinoma, Non-Small- Cell Lung

Interventions

Type	Name	Description
DRUG	SEA-CD40	Given into the vein (IV; intravenously); schedule is cohort-specific
DRUG	pembrolizumab (KEYTRUDA®)	Given by IV; schedule is cohort-specific.
DRUG	pemetrexed	Given by IV on Day 1 of each 21-day cycle.
DRUG	carboplatin	Given by IV on Day 1 of Cycles 1-4. Each cycle will be 21 days long.

Timeline

• Start date: 2021-10-06
• Primary completion: 2024-01-03
• Completion: 2024-11-25
• First posted: 2021-08-06
• Last updated: 2025-05-11
• Results posted: 2025-01-22

Locations

29 sites across 6 countries: United States, Canada, France, Germany, Spain, Sweden

Regulatory

• FDA-regulated drug study